Передопераційна гормональна терапія місцево поширеного раку молочної залози
DOI:
https://doi.org/10.24026/1818-1384.4(37).2011.86405Ключові слова:
breast cancer, neoadjuvant hormone therapy, antiestrogens, aromatase inhibitorsАнотація
Endocrine therapy for locally advanced breast cancer (LABC) has more than a100-year history. Efficiency of its use in adjuvant therapy confirmed by the results of many randomized trials, however, as neoadjuvant antihormonal drug therapy induction drugs are rarely used. The results of many randomized trials on the efficacy of neoadjuvant hormonal ER + and/or ER + breast cancer in postmenopausal women indicate a high response rate from the tumor which allows to achieve objectives neoadjuvant therapy in 40-60% of patients. Optimal drugs for neoadjuvant hormonotherapy are aromatase inhibitors of the third generation (letrozole, anastrozole, exemestane) daily for 3-4 months. Preoperative endocrine therapy development aimed at identifying additional factors (besides the presence of ER and/or RP) which define a positive response from the tumor to treatment and individualize this treatment and maximize clinical outcomes.Посилання
Бюллетень Национального канцер-регистра №11 – "Рак в Украине, 2008-2009", Киев – 2010.
Летягин В.П., Высоцкая И.В. Первичный рак молочной железы (диагностика, лечение, прогноз). – М. 1996. – 160 с.
Моисеенко В.М., Семиглазов В.В., Тюляндин С.А. Современное лекарственное лечение местно-распространенного и метастатического рака молочной железы. – С.-ПБ.: Грифон, 1997. – 254 с.
Семиглазов В.Ф., Нургазиев К.Ш., Арзуманов А.С. Опухоли молочной железы (лечение и профилактика). – Алматы, 2001. – 344 с.
Семиглазов В.Ф., Семиглазов В.В., Иванов В.Г. и др. Гормонотерапия операбельного рака молочной железы // Медицинский академический журнал. – 2003. – Т. 3, № 3. – С. 79-87.
Albain K.S., Barlow W.E., Ravdin P.M., Farrar W.B., Burton G.V., Ketchel S.J., Cobau C.D., Levine E.G., Ingle J.N., Pritchard K.I., Lichter A.S., Schneider D.J., Abeloff M.D., Henderson I.C., Muss H.B., Green S.J., Lew D., Livingston R.B., Martino S., Osborne C.K. Breast Cancer Intergroup of North America. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomized controlled trial // Lancet. – 2009. – Vol. 374, № 9707. – P. 2055-2063. https://doi.org/10.1016/s0140-6736(09)61523-3
Anderson B.O., Yip C.H., Smith R.A., et al. Guideline implementation for breast healthcare in low-income and middle-income countries: Overview of the Breast Health Global Initiative Global Summit 2007 // Cancer. – 2008. – Vol. 113, № S8. – P. 2221-2243. https://doi.org/10.1002/cncr.23844
Beatson G.T. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases // Lancet. – 1896. – Vol. 148, № 3802. – P. 104-107. https://doi.org/10.1016/s0140-6736(01)72307-0
Boyd S. On oophorectomy in cancer in the breast // Br. Med. J. – 1900. Vol. 1, № 2. – P. 1161-1167. https://doi.org/10.1136/bmj.1.1988.257
Cataliotti L., Buzdar A.U., Noguchi S., Bines J., Takatsuka Y., Petrakova K., Dube P., de Oliveira C.T. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative Arimidex Compared to Tamoxifen (PROACT) trial // Cancer. – 2006. – Vol. 106, № 10. – P. 2095-2103. https://doi.org/10.1002/cncr.21872
Eiermann W., Paepke S., Appfelstaedt J., Llombart-Cussac A., Eremin J., Vinholes J., Mauriac L., Ellis M., Lassus M., Chaudri-Ross H.A., Dugan M., Borgs M. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study // Ann. Oncol. – 2001. – Vol. 11, № 12. – P. 1527-1532. https://doi.org/10.1023/a:1013128213451
Ellis M.J., Coop A., Singh B., Mauriac L., Llombert-Cussac A., Janicke F., Miller W.R., Evans D.B., Dugan M., Brady C., Quebe-Fehling E., Borgs M. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial // J. Clin. Oncol. – 2001. – Vol. 19, № 18. – P. 3808-3816. https://doi.org/10.1200/jco.2001.19.18.3808
Ellis M.J., Suman V.J., Hoog J., Lin L., Snider J., Prat A., Parker J.S., Luo J., Deschryver K., Allred D.C., Esserman L.J., Unzeitig G.W., Margenthaler J., Babiera G.V., Marcom P.K., Guenther J.M., Watson M.A., Leitch M., Hunt K., Olson J.A. Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor-Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype – ACOSOG Z1031 // J. Clin. Oncol. – 2011. – Vol. 29, № 17. P. 2342-2349. https://doi.org/10.1200/jco.2010.31.6950
Goldhirsch A., Ingle J.N., Gelber R.D., et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009 // Ann. Oncol. – 2009. – Vol. 20, № 8. – P. 1319-1329. https://doi.org/10.1093/annonc/mdp322
Hortobagyi G.N., Sinngletery S.E., McNesse H.D. Treatment of locally advanced breast cancer // Disease of the Breast, Philadelphia: Lippincott-Raven. – 1996. – P. 585-589.
Jensen E.V., Block G.E., Smith S., et al. Estrogen receptors and breast cancer response to adrenalectomy. In Hall T.C. (ed): Prediction on response in cancer therapy // Monogr. Natl. Cancer Ins. – 1971. – Vol. 34. – P. 55-70.
Jensen E.V., Jacobson H.I. Basic guides to the mechanism of estrogenaction // Recent Prog. Norm. Res. – 1962. – Vol. 18. – P. 387-414.
Jonat W. Zoladex TM (goserelin) vs CMF as adjuvant therapy in pre-/perimenopausal node-positive breast cancer: first efficacy results from ZEBRA Study // Eur J Cancer. – 2000. – Vol. 36, № 5. – P. 67-132.
Jordan V.C. Origins of antiestrogens. In: Estrogens and Antiestrogens: Basic and Clinical Aspect. Lindsay R., Dempster D.W., Jordan V.C. (eds.).Philadelphia, Lippmcott-Raven. – 1997. – № 11. – P. 9-20.
Jordan V.C. The development of tamoxifen for breast cancer therapy: A tribute to the late Arthur L. Walpole // Breast Cancer Res. Treat. – 1988. – Vol. 11. – P. 197-209. https://doi.org/10.1007/bf01807278
Kaufman B., Mackey J.R., Clemens M.R., Bapsy P.P., Vaid A., Wardley A., Tjulandin S., Jahn M., Lehle M., Feyereislova A., Revil C., Jones A. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study // J. Clin. Oncol. – 2009. – Vol. 27, № 33. – P. 5529-5537. https://doi.org/10.1200/jco.2008.20.6847
Kennedy B.J., Kelley R.M., White G., Nathanson I.T. Surgery as an ajunct to hormone therapy of breast cancer // Cancer. – 1957. – Vol. 10, № 5. – P. 1055-1075. https://doi.org/10.1002/1097-0142(195709/10)10:5<1055::aid-cncr2820100528>3.0.co;2-x
Lerner L.J., Holthaus F.J., Thompson C.R. A non-steroidal estrogen antagonist l-(p-2-diethylaminoethoxyphenylh-phenyl-2-p-methoxyphenyl ethanol // Endocrinology. – 1958. – Vol. 63, № 3. – P. 295-318. https://doi.org/10.1210/endo-63-3-295
Marcom P.K., Isaacs C., Harris L., Wong Z.W., Kommarreddy A., Novielli N., Mann G., Tao Y., Ellis M.J. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers // Breast Cancer Res. Treat. – 2007. – Vol. 102, № 1. – P. 43-49. https://doi.org/10.1007/s10549-006-9307-8
McGuire W.L., Carbone P.P., Volmer E.P. et al. Estrogen receptors in human breast cancer // New York: Raven Press. – 1975. – 232 p.
Mlineritsch B., Tausch C., Singer C., Luschin-Ebengreuth G., Jakesz R., Ploner F., Stierer M., Melbinger E., Menzel C., Urbania A., Fridrik M., Steger G., Wohlmuth P., Gnant M., Greil R. Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17) // Breast Cancer Res Treat. – 2008. – Vol. 112, № 1. – P. 203-213. https://doi.org/10.1007/s10549-007-9843-x
Semiglazov V.F., Semiglazov V.V., Dashyan G.A., Ziltsova E.K., Ivanov V.G., Bozhok A.A., Melnikova O.A., Paltuev R.M., Kletzel A., Berstein L.M. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer // Cancer. – 2007. – Vol. 110, № 2. – P. 244-254. https://doi.org/10.1002/cncr.22789
Seo J.H., Kim Y.H., Kim J.S. Meta-analysis of pre-operative aromatase inhibitor versus tamoxifen in postmenopausal woman with hormone receptor-positive breast cancer // Cancer Chemother Pharmacol. – 2009. – Vol. 63, № 2. – P. 261-266. https://doi.org/10.1007/s00280-008-0735-5
Smith I.E., Dowsett M., Ebbs S.R., Dixon J.M., Skene A., Blohmer J.U., Ashley S.E., Francis S., Boeddinghaus I., Walsh G. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial // J. Clin. Oncol. – 2005. – Vol. 23, № 22. – P. 5108-5116. https://doi.org/10.1200/jco.2005.04.005
Torrisi R., Bagnardi V., Pruneri G., Ghisini R., Bottiglieri L., Magni E., Veronesi P., D'Alessandro C., Luini A., Dellapasqua S., Viale G., Goldhirsch A., Colleoni M. Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer // Br. J. Cancer. – 2007. – Vol. 97, № 6. – P. 802-808. https://doi.org/10.1038/sj.bjc.6603947
##submission.downloads##
Опубліковано
Номер
Розділ
Ліцензія
Ця робота ліцензується відповідно до Creative Commons Attribution-NonCommercial 4.0 International License.
